A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at t

Trial Details

NCT ID
NCT07544589
Phase
PHASE1
Sponsor
Dispatch Biotherapeutics
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • DISP-10
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

  • Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma
  • Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Aged ≥18 years at time of signing informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →